MI3 Tech Note on PreveCeutical Medical Inc. (CSE: PREV | OTCQB: PRVCF)

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on PreveCeutical Medical Inc. (CSE: PREV | OTCQB: PRVCF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on PreveCeutical Medical Inc.:

  • PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
  • PreveCeutical has partnered with the University of Queensland in multiple research and development programs. Under the agreements, intellectual property and results arising from these programs will be owned by PreveCeutical.
  • PREV is gaining momentum following good set of news release …
  • PREV traded over 68 Million shares over the last three months between $0.01 & $0.06
  • Support: S2; $ 0.025  S1; $ 0.045  Resistance:   R1; $ 0.06  R2; $0.075

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).


Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.

SOL Global is rapidly becoming the front runner in the US medical cannabis industry

When cannabis comes up in a conversation, it’s quite easy to get the impression that attitudes towards it are changing worldwide, particular in medicinal cannabis. It’s not just an observation, its turning into a fact. Many countries are now legalizing medical cannabis use, including South Korea and Thailand. There’s going to be more to smile about in the country of smiles, and the American and Canadian influence is a big part of it. In the US legal cannabis industry producers have the advantage of being years ahead in the development of this industry.

SOL Global Investments Corp. (CSE: SOL | OTCQB: SOLCF) is an international investment company with a focus on the cannabis industry in legal U.S. states. The Company’s R&D program with the University of Miami is complemented by its strategic investments and partnerships across cultivation, distribution and retail. This comprehensive approach is positioning SOL as a future front-runner in the United States’ medical cannabis industry. Just in April 2019 SOL has undergone rapid growth and is going from strength to strength.

SOL Global acquired a 10.3% stake in Sacred

Announced on April 2, 2019, SOL acquired a 10.3% stake in Sacred, a Chicago based manufacturer of premium hemp seed oil-infused products, including pain relief balms and oils, feminine products, massage oils, salt soaks, and personal lubricants. Investment from SOL will help Sacred pursue Food and Drug Administration approval for its hemp seed oil derived pain relief balms and lotions, with the aim of becoming one of the first hemp companies in the United States to receive FDA approval.

Sacred Hemp CEO Silvia Orizaba said. “SOL’s investment will also help our company fortify and expand our existing product lines, as well as ramp up our consumer outreach efforts.”

SOL Global plans to spin off Scythian Biosciences Inc.

SOL recently announced it plans to spin off its wholly owned subsidiary, Scythian Biosciences Inc., into an independent, publicly traded company. Upon the closing of the spin-off, which is expected to occur on or before September 30, 2019, SOL shareholders will own shares of both companies.

Brady Cobb, CEO of SOL Global stated: “We believe this transaction will unlock value for all of our current SOL shareholders and also remains consistent with SOL’s investment strategy in the cannabis space.”

Scythian Biosciences Inc. (to be renamed Impact Biosciences Corp.) is a research and development company that is developing a proprietary cannabinoid combination drug therapy for the treatment of concussions and traumatic brain injury. Impact’s mission is to be the first accepted drug regimen for concussive treatment. Impact has also been endorsed by Pro Football Legends and the World Boxing Association on its mission.

SOL Global subsidiary 3 Boys Farms LLC. to acquire Merida’s Michigan subsidiary MCP Wellness Inc.

Also in April, SOL Global subsidiary 3 Boys Farms LLC. entered into a binding letter of intent with cannabis focused private equity firm Merida Capital Partners to acquire Merida’s Michigan subsidiary MCP Wellness Inc. for an aggregate purchase price of US$150 million. MCP Wellness currently holds the rights to acquire two Michigan cultivation licenses, a processing license, and 3 fully licensed cannabis provisioning centers’ in Michigan with a fourth provisioning center scheduled to open in May. MCP Wellness plans to open an additional nine municipally approved provisioning centers by August 2019. Assuming plans are completed as scheduled, SOL Global and Merida expect Michigan gross revenue from the acquired business to generate in excess of US$61 million in calendar year 2019 and more than US$121 million in 2020. Now that’s a quick payback on investment.

SOL Global Investments Corp. keeps growing at such a fast rate it’s sometimes hard to keep up with everything that is happening. After a very busy April one could say SOL Global is growing even faster than the cannabis industry, and is positioning themselves as the leading medical cannabis company invested into the US. For investors having your fingers in a few pies could be a good thing as SOL continues their acquisitions and spinning off Scythian Biosciences into an independent, publicly traded company thereby benefiting both the Company and shareholders.

Scythian CEO on the potential impact of cannabinoid drugs on traumatic brain injuries

Jonathan Gilbert, CEO and Director, and David Schrader, COO of Scythian Biosciences Corp. (TSXV: SCYB) (“Scythian”) in an interview with InvestorIntel Senior Editor Peter Clausi discuss the cannabinoid drug Scythian has developed to treat traumatic brain injuries. David states the drug is for immediate use after impact “to try and prevent” continuing brain damage, tissue damage from inflammation and any additional damage from the body’s own immune response. Scythian has partnered with the “world renowned” University of Miami Medical Center, who will be completing the preclinical and clinical testing of Scythian’s cannabinoid drug.

Peter Clausi: Today we are discussing Scythian Biosciences Corp., a biotech company doing research in the cannabinoid space. Could you tell us something about the company?

David Schrader: This company started out in the medical marijuana field in Canada, and has a license application pending. About 2 years ago we changed into the drug development sector where we are focusing on drugs that are marijuana related, cannabinoids and we have one drug currently in testing at the University of Miami.

Peter Clausi: What drug are you testing?

David Schrader: We are testing a drug…It is a combination drug for traumatic brain injury. Whenever somebody gets a head injury, aside from the initial impact, there is a lot of tissue damage that happens after the actual injury.

Peter Clausi: This is what the NFL, CFL and the NHL have been addressing with their concussion protocols. Is that right?

David Schrader: It is, but a lot of the focus on the football arena really is the cumulative effect, CTE, that take place over a long period of time. Our drug is focused on immediately after an impact to try and prevent continuing brain damage that occurs, tissue damage from inflammation and from the body’s own immune response immediately after an injury.

Peter Clausi: You mentioned you are doing research with the University of Miami. Why Miami?

David Schrader: University of Miami Medical Center and the hospital have an amazing staff. They have a division that actually is world renowned, one of the top couple in the country that focuses on brain and spinal cord injuries. We have a team of some of the top doctors in the country who are specialists in different areas relating to brain injuries and spinal cord injuries… to access the complete interview, click here

Disclaimer: Scythian Bioscience Corp. is an advertorial member of InvestorIntel.